Income Statement
CYTOMX THERAPEUTICS, INC.
CTMX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
76.20 | 138.10 | 101.21 | 53.16 | 69.57 | 100.36 | 57.49 | 65.97 | 71.62 | 15.04 | 7.71 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
76.20 | 138.10 | 101.21 | 53.16 | 69.57 | 100.36 | 57.49 | 65.97 | 71.62 | 15.04 | 7.71 |
|
Operating Expenses
|
98.57 | 113.11 | 107.70 | 154.50 | 153.35 | 148.97 | 168.38 | 137.38 | 117.88 | 74.63 | 40.92 |
|
Research & Development
|
68.73 | 83.38 | 77.68 | 111.65 | 114.19 | 112.94 | 131.62 | 103.87 | 92.28 | 54.76 | 28.36 |
|
Selling, General & Administrative
|
29.84 | 29.73 | 30.02 | 42.85 | 39.16 | 36.03 | 36.77 | 33.51 | 25.61 | 19.87 | 12.56 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-22.36 | 25.00 | -6.48 | -101.34 | -83.78 | -48.61 | -110.90 | -71.41 | -46.26 | -59.59 | -33.20 |
|
Non-Operating Income
|
-5.23 | -7.10 | -9.81 | -2.02 | -0.17 | -1.81 | -8.23 | -1.11 | -2.65 | -0.67 | 2.16 |
|
Interest Income
|
5.21 | 7.14 | 9.84 | 1.68 | 0.26 | 1.84 | 8.37 | 7.64 | 2.67 | 2.43 | 1.32 |
|
Interest Expense
|
- | - | - | - | - | - | - | - | - | 1.69 | 1.73 |
|
Other Non-Op Income / Expense
|
0.03 | -0.04 | -0.03 | 0.34 | -0.08 | -0.03 | -0.14 | -0.07 | -0.03 | -0.07 | -1.74 |
|
Income Before Tax
|
-17.13 | 32.09 | 3.32 | -99.32 | -83.61 | -46.80 | -102.67 | -6.46 | -43.61 | -58.92 | -35.36 |
|
Income Tax Expense
|
0.24 | 0.22 | 3.89 | 0.00 | 0.00 | -13.91 | -0.43 | 14.30 | -0.51 | -0.02 | 0.01 |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-17.37 | 31.87 | -0.57 | -99.32 | -83.61 | -32.89 | -102.24 | -84.60 | -43.10 | -58.90 | -35.37 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-22.36 | 25.00 | -6.48 | -101.34 | -83.78 | -48.61 | -110.90 | -69.53 | -44.61 | -57.85 | -32.00 |
|
Earnings Per Share (Basic)
|
- | - | - | - | - | - | - | - | - | - | - |
|
Diluted EPS
|
- | - | - | - | - | - | - | - | - | - | - |
|
Weighted Average Shares
|
137.94 | 84.44 | 73.81 | 65.74 | - | - | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
137.94 | 84.75 | 73.81 | 65.74 | - | - | - | - | - | - | - |
|
Comprehensive Income
|
-17.28 | 31.80 | -0.48 | -99.07 | -83.80 | -32.99 | -102.09 | -84.60 | -43.17 | -58.85 | -35.45 |